Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Science ; 380(6648): 899-901, 2023 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-37262168

RESUMO

The Biden administration seeks to change how agencies weigh the effects of regulation.

2.
Science ; 372(6541): 439, 2021 04 30.
Artigo em Inglês | MEDLINE | ID: mdl-33926927
3.
Health Aff (Millwood) ; 27(6): 1554-9, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18997211

RESUMO

Proposed legislation seeks to impose price transparency in the heath care industry as a remedy for increasing medical device prices. This paper analyzes previous attempts to mandate similar price-disclosure rules in a variety of industries. We identify the economic conditions under which mandatory price disclosure is likely to generate substantial benefits and costs. Applying these conditions, we conclude that mandatory price disclosure for implantable devices is unlikely to pass a benefit-cost test.


Assuntos
Revelação/legislação & jurisprudência , Equipamentos e Provisões/economia , Análise Custo-Benefício , Difusão de Inovações , Medicare , Mecanismo de Reembolso , Estados Unidos
4.
Risk Anal ; 26(3): 641-55, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16834624

RESUMO

Economic analysis of life-saving investments in both the public and private sectors has the potential to dramatically improve longevity and the quality of life, but only if the analyses on which decisions are based are done well. In this article, we analyze a data set that provides information on the content and quality of journal articles that measure the cost-effectiveness of life-saving investments. Our study is the first to provide a detailed multivariate analysis of factors affecting objective measures of quality. We also explore whether a series of recommendations by an expert panel convened by the U.S. Public Health Service affect the way analyses of specific life-saving investments are done. Our results suggest that four factors are positively correlated with an index we construct to measure analytical quality: (1) having at least one author affiliated with a university, (2) publication in a journal that has experience in publishing these analyses, (3) if the life-saving investment is located in the United States, and (4) if the analysis considers a measure of social costs or benefits. Somewhat surprisingly, a study's funding source and whether it is affiliated with industry are not significantly correlated with the quality index. Finally, neither time nor the panel guidelines had an impact on the index.


Assuntos
Economia Médica , Qualidade de Vida , Medição de Risco/métodos , Análise Custo-Benefício , Tomada de Decisões , Farmacoeconomia , Humanos , Investimentos em Saúde , Vida , Modelos Econômicos , Análise Multivariada , Saúde Pública , Anos de Vida Ajustados por Qualidade de Vida , Alocação de Recursos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA